Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG), a pioneer in minimally invasive treatments for severe lung disease, has announced its participation in an upcoming investor event. The company will engage in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on February 27, 2025, at 8:00 AM PT / 11:00 AM ET.

Interested parties can access both live and archived versions of the presentation through the 'Investors' section of the Pulmonx website at investors.pulmonx.com.

News Market Reaction – LUNG

-5.56%

-5.56% Session move

In the trading session that priced this news, LUNG declined 5.56%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^™ Platform, and StratX^® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When is Pulmonx (LUNG) presenting at the Citi 2025 Unplugged Medtech Conference?

Pulmonx (LUNG) will present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025, at 8:00 AM PT / 11:00 AM ET in New York.

How can investors watch Pulmonx's (LUNG) presentation at the Citi 2025 conference?

Investors can watch both the live and archived webcast of Pulmonx's presentation through the 'Investors' section of the company website at investors.pulmonx.com.

What type of presentation will Pulmonx (LUNG) give at the Citi 2025 conference?

Pulmonx will participate in a fireside chat format presentation at the Citi 2025 Unplugged Medtech and Life Sciences Access Day.

Where is the Citi 2025 Unplugged Medtech conference featuring Pulmonx (LUNG) being held?

The Citi 2025 Unplugged Medtech and Life Sciences Access Day featuring Pulmonx will be held in New York.